The upper pulmonary veins (PVs) are responsible for the majority of atrial fibrillation (AF) triggering foci, whereas the inferior PVs are more difficult to ablate and prone to postablation ostial ...

These foci are commonly in the superior pulmonary veins; this is an important factor in the electrophysiologic approach to atrial fibrillation, known as pulmonary vein isolation. Less commonly ...

"Our results provide conclusive evidence for the benefit of pulmonary vein isolation ablation in individuals with symptomatic atrial fibrillation, putting concerns about a substantial placebo ...

Atrial fibrillation is the most common cardiac ... initiated by repetitive discharges originating from the pulmonary veins.

The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

Aggressive ablation provided more favorable outcomes at 12 months than regular ablation in patients with persistent atrial fibrillation ... ablation underwent pulmonary vein isolation (PVI ...

"Second, PFA may yield more durable lesions, thereby reducing pulmonary-vein reconnections ... growing body of evidence supporting the use of PFA for the treatment of atrial fibrillation." "It shows ...

Pulse Biosciences is developing nsPFA technology for cardiac ablation to treat AFib and for ablating benign thyroid nodules.

One of AI’s most immediate impacts is in screening and identifying patients who may have asymptomatic or paroxysmal AF, those ...

Aurobindo Pharma Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) to ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, announced the continuation of the Quick AF study, which evaluates the investigational ...